UBS Group’s vTv Therapeutics VTVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $81.9K | Sell |
2,175
-3,461
| -61% | -$120K | ﹤0.01% | 7293 |
|
|
2026
Q1 | $224K | Buy |
5,636
+3,968
| +238% | +$144K | ﹤0.01% | 6576 |
|
|
2025
Q4 | $66.7K | Sell |
1,668
-1,302
| -44% | -$36.2K | ﹤0.01% | 7085 |
|
|
2025
Q3 | $69.3K | Buy |
2,970
+123
| +4% | +$2.16K | ﹤0.01% | 7337 |
|
|
2025
Q2 | $42.7K | Sell |
2,847
-1,193
| -30% | -$21.9K | ﹤0.01% | 7896 |
|
|
2025
Q1 | $70K | Sell |
4,040
-3,472
| -46% | -$58K | ﹤0.01% | 7329 |
|
|
2024
Q4 | $104K | Buy |
7,512
+6,646
| +767% | +$98.3K | ﹤0.01% | 6851 |
|
|
2024
Q3 | $11.7K | Sell |
866
-3,314
| -79% | -$55K | ﹤0.01% | 7665 |
|
|
2024
Q2 | $73.8K | Buy |
4,180
+2,723
| +187% | +$64.9K | ﹤0.01% | 6389 |
|
|
2024
Q1 | $34.3K | Buy |
+1,457
| New | +$18.5K | ﹤0.01% | 6673 |
|
|
2023
Q2 | – | Sell |
-24
| Closed | -$775 | – | 9709 |
|
|
2023
Q1 | $775 | Sell |
24
-171
| -88% | -$5.8K | ﹤0.01% | 8906 |
|
|
2022
Q4 | $5.14K | Sell |
195
-149
| -43% | -$4.93K | ﹤0.01% | 9213 |
|
|
2022
Q3 | $13K | Buy |
+344
| New | +$13.5K | ﹤0.01% | 8071 |
|
|
2022
Q1 | – | Sell |
-422
| Closed | -$17K | – | 10962 |
|
|
2021
Q4 | $17K | Buy |
+422
| New | +$22.7K | ﹤0.01% | 8084 |
|
|
2021
Q3 | – | Sell |
-265
| Closed | -$24K | – | 10132 |
|
|
2021
Q2 | $24K | Buy |
265
+167
| +170% | +$16.9K | ﹤0.01% | 7154 |
|
|
2021
Q1 | $11K | Sell |
98
-138
| -58% | -$13.6K | ﹤0.01% | 7872 |
|
|
2020
Q4 | $18K | Buy |
236
+22
| +10% | +$1.69K | ﹤0.01% | 7023 |
|
|
2020
Q3 | $15K | Buy |
214
+106
| +98% | +$9.32K | ﹤0.01% | 6539 |
|
|
2020
Q2 | $9K | Buy |
108
+83
| +332% | +$8.2K | ﹤0.01% | 7097 |
|
|
2020
Q1 | $2K | Hold |
25
| – | – | ﹤0.01% | 7655 |
|
|
2019
Q4 | $2K | Hold |
25
| – | – | ﹤0.01% | 7853 |
|
|
2019
Q3 | $2K | Sell |
25
-229
| -90% | -$12.9K | ﹤0.01% | 7754 |
|
|
2019
Q2 | $14K | Buy |
254
+187
| +279% | +$11.2K | ﹤0.01% | 6860 |
|
|
2019
Q1 | $5K | Sell |
67
-95
| -59% | -$9.21K | ﹤0.01% | 7189 |
|
|
2018
Q4 | $18K | Sell |
162
-88
| -35% | -$8.14K | ﹤0.01% | 6880 |
|
|
2018
Q3 | $8K | Buy |
250
+223
| +826% | +$10.5K | ﹤0.01% | 7293 |
|
|
2018
Q2 | $2K | Buy |
27
+2
| +8% | +$148 | ﹤0.01% | 7745 |
|
|
2018
Q1 | $4K | Buy |
25
+7
| +39% | +$1.71K | ﹤0.01% | 7352 |
|
|
2017
Q4 | $4K | Buy |
18
+12
| +200% | +$2.69K | ﹤0.01% | 7478 |
|
|
2017
Q3 | $1K | Sell |
6
-2
| -25% | -$399 | ﹤0.01% | 7597 |
|
|
2017
Q2 | $1K | Buy |
8
+2
| +33% | +$417 | ﹤0.01% | 7524 |
|
|
2017
Q1 | $2K | Sell |
6
-24
| -80% | -$5.47K | ﹤0.01% | 7308 |
|
|
2016
Q4 | $6K | Buy |
+30
| New | +$6.89K | ﹤0.01% | 7169 |
|
Other funds holding VTVT
SB
SL
BBA
TECP
ACM
UBS Group's VTVT Position: Q2 2026 in Review
UBS Group reduced its vTv Therapeutics (VTVT) stake by 61% in Q2 2026, selling an estimated $120K and leaving 2,175 shares worth $81.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7293.
UBS Group first reported a position in VTVT in Q4 2016 and has held it in 33 quarters since. The position peaked at $224K in Q1 2026. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.
- UBS Group held 2,175 shares of vTv Therapeutics worth $81.9K as of Q2 2026.
- UBS Group sold 3,461 vTv Therapeutics shares in Q2 2026, an estimated $120K.
- vTv Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7293 holding.
- UBS Group first reported a position in vTv Therapeutics in Q4 2016 and has held it in 33 quarters since.
- UBS Group's vTv Therapeutics position peaked at $224K in Q1 2026.
- 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.